NASDAQ: CMMB - Chemomab Therapeutics Ltd.

Yield per half year: -18.57%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Chemomab Therapeutics Ltd.

Extended chart Simple chart
Financial Markets by TradingView

About Chemomab Therapeutics Ltd.

Chemolab Therapeutics Ltd., биотехнологическая компания клинической стадии, открывает и разрабатывает терапевтические средства для лечения фиброзных и воспалительных заболеваний. Ведущим клиническим продуктом компании является CM-101, гуманизированное моноклональное антитело, прошедшее фазу 2a клинических испытаний, которое препятствует основной функции растворимого хемокина CCL24 для лечения первичного склерозирующего холангита (ПСХ) и системной склеродермии (ССД). Ранее компания называлась Anchiano Therapeutics Ltd., а в марте 2021 года сменила название на Chemob Therapeutics Ltd.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2019-02-12
ISIN US16385C1045
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.chemomab.com
Цена ао 1.16
Change price per day: -0.0281% (1.067)
Change price per week: +4.58% (1.02)
Change price per month: -23.26% (1.39)
Change price per 3 month: -46.13% (1.98)
Change price per half year: -18.57% (1.31)
Change price per year: +46.12% (0.73)
Change price per 3 year: -74.72% (4.22)
Change price per 5 year: +64.11% (0.65)
Change price per year to date: -32.91% (1.59)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.3526 10
P/E 0 0
EV/EBITDA 0.1178 10
Total: 5

Efficiency

Title Value Grade
ROA, % -109.06 0
ROE, % -142.13 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0155 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % -5.37 0
Yield EPS, % -85.9 0
Total: 1.2
More

Institutions Volume Share, %
Orbimed Advisors LLC. 2241274 0
Cormorant Asset Management, LP 288169 15.66
Ikarian Capital, LLC 236709 12.87
KESTRA PRIVATE WEALTH SERVICES, LLC 31241 1.7
Two Sigma Investments, LP 30263 1.65
BOOTHBAY FUND MANAGEMENT, LLC 26529 1.44
Two Sigma Advisers, LP 11800 0.64
Geode Capital Management, LLC 11737 0.64
Advisory Services Network, LLC 11173 0.61
Morgan Stanley 7800 0.42



Head Job title Payment Year of birth
Dr. Adi Mor George Ph.D. Co-Founder, Chief Scientific Officer, CEO & Executive Director 435.4k 1982 (43 years)
Barbara Lindheim Consulting Vice President of Investor & Public Relations, Strategic Communications N/A
Dr. Matthew B. Frankel M.B.A., M.D. Chief Medical Officer & VP of Drug Development N/A 1969 (56 years)
Ms. Sigal Fattal CPA, M.B.A. Chief Financial Officer 258k 1971 (54 years)
Mr. Jack Lawler Senior VP of Global Clinical Development Operations

Address: Israel, Tel Aviv, Building 7 - open in Google maps, open in Yandex maps
Website: https://www.chemomab.com